A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
Clinical trial NCT05370521 · TERMINATED
Trial details
- NCT number
- NCT05370521
- Sponsor
- Spruce Biosciences
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-15
- Primary completion
- 2023-08-03
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.